1
|
Ebrahimnia M, Alavi S, Vaezi H, Karamat Iradmousa M, Haeri A. Exploring the vast potentials and probable limitations of novel and nanostructured implantable drug delivery systems for cancer treatment. EXCLI JOURNAL 2024; 23:143-179. [PMID: 38487087 PMCID: PMC10938236 DOI: 10.17179/excli2023-6747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Figures] [Subscribe] [Scholar Register] [Received: 10/30/2023] [Accepted: 01/08/2024] [Indexed: 03/17/2024]
Abstract
Conventional cancer chemotherapy regimens, albeit successful to some extent, suffer from some significant drawbacks, such as high-dose requirements, limited bioavailability, low therapeutic indices, emergence of multiple drug resistance, off-target distribution, and adverse effects. The main goal of developing implantable drug delivery systems (IDDS) is to address these challenges and maintain anti-cancer drugs directly at the intended sites of therapeutic action while minimizing inevitable side effects. IDDS possess numerous advantages over conventional drug delivery, including controlled drug release patterns, one-time drug administration, as well as loading and stabilizing poorly water-soluble chemotherapy drugs. Here, we summarized conventional and novel (three-dimensional (3D) printing and microfluidic) preparation techniques of different IDDS, including nanofibers, films, hydrogels, wafers, sponges, and osmotic pumps. These systems could be designed with high biocompatibility and biodegradability features using a wide variety of natural and synthetic polymers. We also reviewed the published data on these systems in cancer therapy with a particular focus on their release behavior. Various release profiles could be attained in IDDS, which enable predictable, adjustable, and sustained drug releases. Furthermore, multi-step or stimuli-responsive drug release could be obtained in these systems. The studies mentioned in this article have proven the effectiveness of IDDS for treating different cancer types with high prevalence, including breast cancer, and aggressive cancer types, such as glioblastoma and liver cancer. Additionally, the challenges in applying IDDS for efficacious cancer therapy and their potential future developments are also discussed. Considering the high potential of IDDS for further advancements, such as programmable release and degradation features, further clinical trials are needed to ensure their efficiency. The overall goal of this review is to expand our understanding of the behavior of commonly investigated IDDS and to identify the barriers that should be addressed in the pursuit of more efficient therapies for cancer. See also the graphical abstract(Fig. 1).
Collapse
Affiliation(s)
- Maryam Ebrahimnia
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Sonia Alavi
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- College of Pharmacy, University of Illinois Chicago, Chicago, IL 60612, USA
| | - Hamed Vaezi
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mahdieh Karamat Iradmousa
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Azadeh Haeri
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
- Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Lin W, Li Y, Shi Q, Liao X, Zeng Y, Tian W, Xie X, Liu H. Preparation and evaluation of bilayer-core osmotic pump tablets contained topiramate. PLoS One 2022; 17:e0264457. [PMID: 35213658 PMCID: PMC8880887 DOI: 10.1371/journal.pone.0264457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Accepted: 02/10/2022] [Indexed: 11/18/2022] Open
Abstract
Topiramate (TPM) was an antiepileptic agent commonly used in clinical. Studies showed that an oral preparation of TPM with extended-release manner could bring some benefits for epileptics. In this paper, controlled release push-pull osmotic pump (PPOP) tablets of sparingly water-soluble TPM were successfully prepared. This bi-layer tablet core mainly consisted of sodium chloride as osmotic promoting agent and polyethylene oxide as suspending and pushing agents. The influences of osmotic agents, pushing agents and the compositions of coating membrane on TPM release profiles were evaluated. An optimal formulation of TPM-PPOP was obtained through single-factor experiments. In vitro release tests showed that the optimum formulation could release TPM at an approximate zero-order rate up to 8 h. Pharmacokinetic behaviors of TPM-PPOP tablets were evaluated and compared with the immediate release capsules after an oral single dose in beagle dogs. Pharmacokinetics results demonstrated that the TPM-PPOP tablet was able to provide a prolonged release of TPM with longer tmax and mean residence time. Lower fluctuations of drug plasma levels could also be achieved with TPM-PPOP tablets. These results suggested that sparely water-soluble drugs as TPM can be designed to PPOP for efficacy and safety use.
Collapse
Affiliation(s)
- Wen Lin
- Department of Clinical Laboratory, Huangshi Love & Health Hospital of Hubei Province, Huangshi, Hubei, China
| | - Yinke Li
- Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, Hubei, China
| | - Qiongzhi Shi
- Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, Hubei, China
| | - Xiangru Liao
- Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, Hubei, China
| | - Yuan Zeng
- Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, Hubei, China
| | - Wei Tian
- Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, Hubei, China
| | - Xiangyang Xie
- Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, Hubei, China
| | - Hui Liu
- Department of Pharmacy, General Hospital of Central Theater of the PLA, Wuhan, Hubei, China
| |
Collapse
|
3
|
Pooresmaeil M, Javanbakht S, Namazi H, Shaabani A. Application or function of citric acid in drug delivery platforms. Med Res Rev 2021; 42:800-849. [PMID: 34693555 DOI: 10.1002/med.21864] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 08/02/2021] [Accepted: 10/12/2021] [Indexed: 12/11/2022]
Abstract
Nontoxic materials with natural origin are promising materials in the designing and preparation of the new drug delivery systems (DDSs). Today's, citric acid (CA) has attracted a great deal of attention because of its special features; green nature, biocompatibility, low price, biodegradability, and commercially available property. So, CA has been employed in the preparation of the various platforms to induce a suitable property on their structure. Recently, several research groups investigated the CA-based platforms in different forms like tablets, dendrimers, hyperbranched polymers, (co)polymer, hydrogels, and nanoparticles as efficient DDSs. By considering an increasing amount of published articles in this field, for the first time, in this review, an overview of the published works regarding CA applications in the design of various DDSs is presented with a detailed and insightful discussion.
Collapse
Affiliation(s)
- Malihe Pooresmaeil
- Polymer Research Laboratory, Department of Organic and Biochemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran
| | | | - Hassan Namazi
- Polymer Research Laboratory, Department of Organic and Biochemistry, Faculty of Chemistry, University of Tabriz, Tabriz, Iran.,Research Center for Pharmaceutical Nanotechnology (RCPN), Tabriz University of Medical Science, Tabriz, Iran
| | - Ahmad Shaabani
- Faculty of Chemistry, Shahid Beheshti University, Tehran, Iran
| |
Collapse
|
4
|
Chen F, Liu H, Wang B, Yang L, Cai W, Jiao Z, Yang Z, Chen Y, Quan Y, Xiang X, Wang H. Physiologically Based Pharmacokinetic Modeling to Understand the Absorption of Risperidone Orodispersible Film. Front Pharmacol 2020; 10:1692. [PMID: 32116683 PMCID: PMC7008171 DOI: 10.3389/fphar.2019.01692] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2019] [Accepted: 12/26/2019] [Indexed: 11/13/2022] Open
Abstract
Objective The aim of the present study was to investigate the absorption routes as well as the potential application of the oral transmucosal delivery of risperidone orodispersible film (ODF) using physiologically based pharmacokinetic modeling. Methods The pharmacokinetic study after intragastric (i.g.), supralingual, and sublingual administration of risperidone ODF was conducted in Beagle dogs. Then a mechanic absorption model which combined Oral Cavity Compartment Absorption and Transit (OCCAT) model with Advanced Compartment Absorption and Transit (ACAT) model for predicting the absorption routes of risperidone ODF in vivo was constructed using GastroPlus™. A sensitivity analysis was performed to investigate the impact of oral residence time on the in vivo absorption of risperidone ODF. Based on the fraction of intraoral absorption, the potential of the oral transmucosal delivery of risperidone were predicted. Results There were no statistical differences in the AUC0-t (P = 0.4327), AUC0-∞ (P = 0.3278), Cmax (P = 0.0531), and Tmax (P = 0.2775) values among i.g., supralingual, and sublingual administration of risperidone ODF in Beagle dogs. The predicted absorption percentage via oral mucosa at oral residence time of 2 min, 5 min, and 10 min was 7.0%, 11.4%, and 19.5%, respectively. No obvious difference was observed for the bioavailability of risperidone ODF within 10 min of oral residence time. The PBPK absorption model for risperidone could be simplified to include ACAT model solely. Conclusion The main absorption route for risperidone ODF was the gastrointestine. The absorption percentage via oral mucosa was almost negligible due to the physicochemical properties of risperidone although ODF dissolved completely in the oral cavity of Beagle dogs within 2 min.
Collapse
Affiliation(s)
- Fang Chen
- National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Hongrui Liu
- National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Bing Wang
- National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Liuliu Yang
- National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China
| | - Weimin Cai
- Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China
| | - Zheng Jiao
- Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Zhou Yang
- Department of General Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China
| | - Yusheng Chen
- Department of General Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China
| | - Yingjun Quan
- Department of General Surgery, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China
| | - Xiaoqiang Xiang
- Department of Clinical Pharmacy, School of Pharmacy, Fudan University, Shanghai, China
| | - Hao Wang
- National Pharmaceutical Engineering Research Center, China State Institute of Pharmaceutical Industry, Shanghai, China
| |
Collapse
|
5
|
Li N, Fan L, Wu B, Dai G, Jiang C, Guo Y, Wang D. Preparation and in vitro/in vivo evaluation of azilsartan osmotic pump tablets based on the preformulation investigation. Drug Dev Ind Pharm 2019; 45:1079-1088. [PMID: 30909753 DOI: 10.1080/03639045.2019.1593441] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
The objective of this study was to design and evaluate azilsartan osmotic pump tablets. Preformulation properties of azilsartan were investigated for formulation design. Azilsartan osmotic pump tablets were prepared by incorporation of drug in the core and subsequent coating with cellulose acetate and polyethylene glycol 4000 as semi-permeable membrane, then drilled an orifice at the center of one side. The influence of different cores, compositions of semipermeable membrane and orifice diameter on azilsartan release were evaluated. The formulation of core tablet was optimized by orthogonal design and the release profiles of various formulations were evaluated by similarity factor (f2). The optimal formulation achieved to deliver azilsartan at an approximate zero-order up to 14 h. The pharmacokinetic study was performed in beagle dogs. The azilsartan osmotic pump tablets exhibited less fluctuation in blood concentration and higher bioavailability compared to immediate-release tablets. Moreover, there was a good correlation between the in vitro dissolution and in vivo absorption of the tablets. In summary, azilsartan osmotic pump tablets presented controlled release in vitro, high bioavailability in vivo and a good in vitro-in vivo correlation.
Collapse
Affiliation(s)
- Nini Li
- a School of Pharmacy , Anhui University of Chinese Medicine , Hefei , Anhui , China
| | - Ling Fan
- a School of Pharmacy , Anhui University of Chinese Medicine , Hefei , Anhui , China.,b Clinical Drug Trial Institution , The First Affiliated Hospital of Bengbu Medical College , Bengbu , Anhui , China
| | - Biao Wu
- c Hefei Jiunuo Pharmaceutical Technology CO., LTD , Hefei , Anhui , China
| | - Genlai Dai
- c Hefei Jiunuo Pharmaceutical Technology CO., LTD , Hefei , Anhui , China
| | - Chengjun Jiang
- a School of Pharmacy , Anhui University of Chinese Medicine , Hefei , Anhui , China
| | - Yan Guo
- a School of Pharmacy , Anhui University of Chinese Medicine , Hefei , Anhui , China
| | - Dianlei Wang
- a School of Pharmacy , Anhui University of Chinese Medicine , Hefei , Anhui , China
| |
Collapse
|
6
|
Sun Y, Zhu S, Lu W, Chen J, Sun C, Guo Y, Wang B, Gao S, Fang W, Hu R. A novel enteric positioning osmotic pump capsule-based controlled release system of sinomenine hydrochloride: In vitro and in vivo evaluation. J Drug Deliv Sci Technol 2019. [DOI: 10.1016/j.jddst.2018.11.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
7
|
Yin J, Wang W, Xu X, Li H, Cong M, Zhao X, Wang C. Preparation, characterization and pharmacokinetics of extended-release tablets of marine polysaccharide drug. J Drug Deliv Sci Technol 2018. [DOI: 10.1016/j.jddst.2017.10.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
|
8
|
Bahari LA, Javadzadeh Y, Jalali MB, Johari P, Nokhodchi A, Shokri J. Nano-suspension coating as a technique to modulate the drug release from controlled porosity osmotic pumps for a soluble agent. Colloids Surf B Biointerfaces 2017; 153:27-33. [PMID: 28208062 DOI: 10.1016/j.colsurfb.2017.02.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2016] [Revised: 02/02/2017] [Accepted: 02/06/2017] [Indexed: 11/19/2022]
Abstract
In controlled porosity osmotic pumps (CPOP), usually finding a single solvent with a capability to dissolve both film former (hydrophobic) and pore former (hydrophilic) is extremely challenging. Therefore, the aim of the present investigation was to tackle the issue associated with controlled porosity osmotic pump (CPOP) system using nano-suspension coating method. In the present study 4-Amino pyridine was used as a highly water soluble drug. In this method, a hydrophilic pore former (sucrose or mannitol) in nano range was suspended in polymeric coating solution using ball-mill. The performance of the prepared formulations was assessed in terms of D12h (cumulative release percent after 12h), Devzero (mean percent deviation of drug release from zero order kinetic), tL (lag time of the drug release) and RSQzero. The results revealed that gelling agent amount (HPMC E15LV) in core and pore former concentration in SPM had crucial effect on SPM integrity. All the optimised formulations showed a burst drug release due to fast dissolving nature of the pore formers. Results obtained from scanning electron microscopy demonstrated the formation of nanopores in the membrane where the drug release takes place via these nanopores. Nano suspension coating method can be introduced as novel method in formulation of CPOPs.
Collapse
Affiliation(s)
- Leila Azharshekoufeh Bahari
- Drug Applied Research Centre (DARC) and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51664, Iran
| | - Yousef Javadzadeh
- Drug Applied Research Centre (DARC) and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51664, Iran; Biotechnology Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51664, Iran
| | - Mohammad Barzegar Jalali
- Drug Applied Research Centre (DARC) and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51664, Iran; Research Center for Pharmaceutical Nanotechnology and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51664, Iran
| | - Peyvand Johari
- Drug Applied Research Centre (DARC) and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51664, Iran
| | - Ali Nokhodchi
- Pharmaceutics Research Laboratory, School of Life Sciences, University of Sussex, Brighton, UK.
| | - Javad Shokri
- Drug Applied Research Centre (DARC) and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz 51664, Iran; Dermatology and Dermopharmacy Research Team (DDRT), Tabriz University of Medical Sciences, Iran.
| |
Collapse
|
9
|
Yang Y, Zhao Z, Wang Y, Yang L, Liu D, Yang X, Pan W. A novel asymmetric membrane osmotic pump capsule with in situ formed delivery orifices for controlled release of gliclazide solid dispersion system. Int J Pharm 2016; 506:340-50. [PMID: 27132166 DOI: 10.1016/j.ijpharm.2016.04.061] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2015] [Revised: 04/07/2016] [Accepted: 04/25/2016] [Indexed: 10/21/2022]
Abstract
In this study, a novel asymmetric membrane osmotic pump capsule of gliclazide (GLC) solid dispersion was developed to achieve a controlled drug release. The capsule shells were obtained by wet phase inversion process using cellulose acetate as semi-permeable membrane, glycerol and kolliphor P188 as pore formers, then filled with the mixture of GLC solid dispersion and pH modifiers. Differentiate from the conventional formulations, sodium carbonate was chosen as the osmotic agent and effervescent agent simultaneously to control the drug release, instead of the polymer materials. The ternary solid dispersion of GLC, with polyethylene glycol 6000 and kolliphor P188 as carriers, was prepared by solvent-evaporation method, realizing a 2.09-fold increment in solubility and dissolution rate in comparison with unprocessed GLC. Influence of the composition of the coating solution and pH modifiers on the drug release from the asymmetric membrane capsule (AMC) was investigated. The ultimate cumulative release of the optimal formulation reached 91.32% in an approximately zero-order manner. The osmotic pressure test and dye test were conducted to validate the drug release mechanism from the AMC. The in vivo pharmacokinetic study of the AMC indicated a 102.66±10.95% relative bioavailability compared with the commercial tablet, suggesting the bioequivalence between the two formulations. Consequently, the novel controlled delivery system with combination of solid dispersion and AMC system is capable of providing a satisfactory alternative to release the water-insoluble drugs in a controlled manner.
Collapse
Affiliation(s)
- Yue Yang
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China
| | - Zhinan Zhao
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China
| | - Yongfei Wang
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China
| | - Lu Yang
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China
| | - Dandan Liu
- School of Biomedical & Chemical Engineering, Liaoning Institute of Science and Technology, Benxi 117004, PR China
| | - Xinggang Yang
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China.
| | - Weisan Pan
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, 103 Wenhua Road, Shenyang 110016, PR China.
| |
Collapse
|
10
|
Zhao S, Yu F, Liu N, Di Z, Yan K, Liu Y, Li Y, Zhang H, Yang Y, Yang Z, Li Z, Mei X. Synchronous delivery of felodipine and metoprolol tartrate using monolithic osmotic pump technology. Drug Dev Ind Pharm 2016; 42:1723-31. [PMID: 27074758 DOI: 10.3109/03639045.2016.1171332] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The synchronous sustained-release of two drugs was desired urgently for patients needing combination therapy in long term. However, sophisticated technologies were used generally to realize the simultaneous delivery of two drugs especially those with different physico-chemical properties. The purpose of this study was to obtain the concurrent release of felodipine and metoprolol tartrate, two drugs with completely different solubilities, in a simple monolithic osmotic pump system (FMOP). Two types of blocking agents were used in monolithic osmotic pump tablets and the synchronous sustained-release of FMOP was acquired in vitro. The tablets were also administered to beagle dogs and the plasma levels of FMOP were determined by HPLC-MS/MS. The pharmacokinetic parameters were calculated using a non-compartmental model. Cmax of both felodipine and metoprolol from the osmotic pump tablets were lower, tmax and mean residence time of both felodipine and metoprolol from the osmotic pump tablets were longer significantly than those from immediate release tablets. These results verified prolonged release of felodipine and metoprolol tartrate from osmotic pump formulations. The similar absorption rate between felodipine and metoprolol in beagles was also obtained by this osmotic pump formulation. Therefore, it could be supposed that the accordant release of two drugs with completely different solubilities may be realized just by using monolithic osmotic pump technology.
Collapse
Affiliation(s)
- Shiqing Zhao
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Fanglin Yu
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Nan Liu
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Zhong Di
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Kun Yan
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Yan Liu
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Ying Li
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Hui Zhang
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Yang Yang
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Zhenbo Yang
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Zhiping Li
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| | - Xingguo Mei
- a Beijing Institute of Pharmacology and Toxicology , Beijing , People's Republic of China
| |
Collapse
|
11
|
Li Z, Yu F, Di Z, Zhao X, Zhao S, Liu Y, Li Y, Wang Z, Gong W, Zhang H, Yang Y, Xie X, Mei X. Development and uniform evaluation of ropinirole osmotic pump tablets with REQUIP XL both in vitro and in beagle dogs. Drug Dev Ind Pharm 2015; 42:12-18. [PMID: 25830369 DOI: 10.3109/03639045.2015.1020219] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
REQUIP XL, prolonged release formulation of ropinirole hydrochloride (RH) in market, could release ropinirole constantly and showed satisfactory therapeutic effect and good compliance. REQUIP XL was composed of more than 10 kinds of excipients and prepared by Geomatrix technology, which was complex and laborious. The purpose of this study was to obtain a dosage form of RH with similar in vitro release profile and bioequivalence in vivo compared to REQUIP XL. Osmotic pump tablet combined with fast release phase was selected as the delivery system of RH and similar release curves were obtained in different media. The tablets were also administered to beagle dogs and the pharmacokinetic parameters were calculated using a non-compartmental model. Cmax, tmax, mean residence time (MRT), and area under the curve from 0 to 24 h (AUC0-24) were 3.97 ± 0.53 ng/mL, 3.58 ± 0.49 h, 8.29 ± 0.93 h, and 35.20 ± 8.11 ng/mL ċ h for ropinirole osmotic pump tablets (ROPT) and 4.15 ± 1.07 ng/mL, 2.92 ± 0.49 h, 7.84 ± 1.09 h, and 34.34 ± 10.06 ng/mL ċ h for REQUIP XL. The log-transformed mean Cmax and AUC0-24 of ROPT were about 92.15% and 102.49% relative to that of REQUIP XL, respectively. The 90% confidence intervals of Cmax and AUC0-24 for ROPT were 75.69-115.31% and 88.89-122.30%, respectively. So it could be concluded that ROPT was uniform with REQUIP XL both in vitro and in beagles and the release profiles of Geomatrix technology may be obtained by osmotic pump combined with fast release technology.
Collapse
Affiliation(s)
- Zhiping Li
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Fanglin Yu
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Zhong Di
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Xiqing Zhao
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Shiqing Zhao
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Yan Liu
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Ying Li
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Zhiyuan Wang
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Wei Gong
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Hui Zhang
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Yang Yang
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Xiangyang Xie
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| | - Xingguo Mei
- a Pharmaceutical Research Department , Beijing Institute of Pharmacology and Toxicology , Beijing , China
| |
Collapse
|